Tuesday, May 10, 2011 – A new study by researchers at Wake Forest Baptist Medical Center sheds light on what causes certain kidneys to do better than others after being transplanted, providing doctors with an easy way to screen for donor kidneys that have the best chance of survival.
"It's been long observed that kidneys taken from some black donors just don't last as long as those taken from non-black donors, and the reason for that has not been known," said Barry I. Freedman, M.D., John H. Felts III Professor and senior investigator. "This study reveals that the genetic profile of the donor has a marked affect on graft survival after transplantation. We now know that these organs aren't failing because they came from black donors, but rather because they came from individuals with two copies of a specific recessive gene."
The study appears in the May issue of the American Journal of Transplantation.
Freedman and co-researchers at Wake Forest Baptist examined 12 years' worth of medical records dating back to 1998, looking for all patients who received a kidney transplant from a black deceased donor whose genetic information had been recorded. The search yielded 106 black donors – from whom one or both kidneys were transplanted – for a total of 136 donated kidneys.
The researchers identified that kidneys from donors who had specific coding changes in a gene called apolipoprotein L1 (APOL1) did not last as long after transplant as those from donors without these changes. These coding changes in the APOL1 gene that affect kidney transplant function are found in about 10 to 12 percent of black individuals. Recent studies, led by Freedman and his colleagues, have shown that these genetic changes are associated with an increased risk of kidney disease, which prompted researchers to investigate the role of these changes in transplant success.
"In looking at the records and follow-up of the recipients of these organs, we accounted for all the usual factors that are known to contribute to more rapid loss of kidney function after transplant," said Freedman, chief of the section on nephrology. "What we found was that the kidney disease-causing risk variants in APOL1 were the strongest predictor of graft loss after transplant. The effect of having two copies of this gene was stronger than the impact of genetic matching between donor and recipient, the amount of time the organ was out of the body, and the antibody levels. APOL1 dwarfed all these other factors known to affect survival."
If the finding is confirmed by other researchers, it has the potential to dramatically improve outcomes for both the individuals undergoing kidney transplantation and those considering kidney donation, Freedman said. It could revolutionize donor selection criteria, allowing transplant physicians the ability to identify kidneys that are likely to function for shorter periods of time. In addition, this screening tool has the potential to help doctors protect potential donors who may be at risk of developing kidney disease down the road.
"It is exciting to see that research done at Wake Forest Baptist could impact kidney transplantation throughout the world," Freedman said. "We have shown for the first time that genetic risk variants in kidney donors are associated with markedly different outcomes after kidney transplantation. This finding could dramatically change the way we practice."
Co-authors on the study, funded by the National Institutes of Health, were: lead author Amber M. Reeves-Daniel, D.O., John A. DePalma, D.O., Anthony J. Bleyer, M.D., Michael V. Rocco, M.D., MSCE, Mariana Murea, M.D., Patricia L. Adams, M.D., Carl D. Langefeld, Ph.D., Donald W. Bowden, Ph.D., Pamela J. Hicks, B.S., Robert J. Stratta, M.D., Jen-Jar Lin, M.D., David F. Kiger, B.S., Michael D. Gautreaux, Ph.D., and Jasmin Divers, Ph.D., all of Wake Forest Baptist.
Media Relations Contacts: Jessica Guenzel, firstname.lastname@example.org, (336) 716-3487; or Bonnie Davis, email@example.com, (336) 716-4977.
Wake Forest Baptist Medical Center (www.wakehealth.edu) is a fully integrated academic medical center located in Winston-Salem, N.C. Wake Forest School of Medicine directs the education and research components, with the medical school ranked among the nation's best and recognized as a leading research center in regenerative medicine, cancer, the neurosciences, aging, addiction and public health sciences. Piedmont Triad Research Park, a division of Wake Forest Baptist, fosters biotechnology innovation in an urban park community. Wake Forest Baptist Health, the clinical enterprise, includes a flagship tertiary care hospital for adults, Brenner Children's Hospital, a network of affiliated community-based hospitals, physician practices and outpatient services. The institution's clinical programs and the medical school are consistently recognized as among the best in the country by U.S.News & World Report.
Jessica Guenzel | EurekAlert!
Transforming plant cells from generalists to specialists
07.12.2016 | Duke University
What happens in the cell nucleus after fertilization
06.12.2016 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Earth Sciences
07.12.2016 | Earth Sciences
07.12.2016 | Materials Sciences